Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Adv Drug Deliv Rev. 2018 Jan 31;127:20–34. doi: 10.1016/j.addr.2018.01.016

Fig. 8.

Fig. 8

Long-term response of cell encapsulated alginate depots (Adapted with permission from reference [118]). (A) Representative dark-field, bright-field, and z-stacked confocal immunofluorescence images of SC-β cell implants. (B) Proteomic analysis of lysates from SC-β cell cluster implants retrieved from the STZ-treated C57BL/6J mice after 90 d implantation. (C) BGL in healthy mice or diabetic mice implanted with SC-β cell-encapsulated TMTD-1.5 spheres. (D) BGL of the STZ-treated C57BL/6 mice with or without TMTD alginate implantation that were subjected to an IVGTT after 174 d. (E) Blood human C-peptide levels of diabetic mice implanted with TMTD-1.5 spheres.